Introduction: Anti-programmed cell death protein 1 (PD-1) therapy can lead to unconventional tumor responses, including radiologic pseudoprogression. Here we have determined the real-world incidence of radiologic pseudoprogression in advanced NSCLC and compared radiologic response criteria for assessment of disease response.
Methods:
The electronic medical records of all patients with NSCLC who were receiving anti-PD-1 therapy at our institution over a 3-year period were retrospectively reviewed, and patients with clinically suspected radiologic pseudoprogression were identified. Patients without available follow-up imaging or clinical data were excluded. Imaging examinations were then analyzed to determine whether progression was confirmed on subsequent reimaging. Assessments of tumor response by the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 (RECIST 1.1), the unidimensional immune-related response criteria (iRRC), and the iRECIST criteria for all patients were performed and compared.
Results: A total of 228 consecutive patients began receiving anti-PD-1 therapy over a 3-year period. Of the 166 of these patients who were evaluable, most (80%) received nivolumab. Fifteen patients (9%) were clinically suspected of having radiologic pseudoprogression on account of tumor enlargement and/or development of new lesions on computed tomography images during the first 4 to 6 weeks of therapy, and they continued receiving anti-PD-1 therapy. Three of these patients (2%) demonstrated evidence of radiologic pseudoprogression at first reimaging. The iRRC and immune RECIST criteria were more accurate in classifying radiologic pseudoprogression as nonprogression; none of the three cases were deemed progression by the iRRC or immune RECIST, whereas all three cases were
Introduction
Therapy with immune checkpoint inhibitors can lead to unconventional tumor responses resulting from immune activation. [1] [2] [3] Here we have sought to determine the incidence of clinically suspected radiologic pseudoprogression in real-world routine clinical management of patients with advanced NSCLC. Radiologic pseudoprogression describes an unconventional imaging pattern of tumor response in which tumors initially exhibit features of progression, including tumor enlargement and/or development of new lesions, with a subsequent radiologic tumor response that is evident on serial imaging with sustained therapy. 1 Radiologic pseudoprogression is initially radiologically indistinguishable from true disease progression and presents a challenge to assessment of therapeutic response in patients receiving immune checkpoint inhibitors, including antiprogrammed cell death protein 1 (PD-1) and anti-cytotoxic-T-lymphocyte-associated antigen 4 therapeutics. [1] [2] [3] Although radiologic pseudoprogression has been reported as occurring in approximately 5% of patients with NSCLC who are receiving anti-PD-1 therapy, 4, 5 there are few data on the incidence of clinically suspected pseudoprogression in routine clinical management. Additionally, for clinical trial purposes, it is useful to know the performance of quantitative measures of tumor response, particularly that of the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 (RECIST 1.1) 6 ; the unidimensional immune-related response criteria 7 (iRRC) ( Table 1) ; and most recently, the immune RECIST (iRECIST). 8 The RECIST 1.1 criteria are the currently accepted response criteria for solid tumors, including NSCLC, and they are in widespread use in clinical trials. These criteria, which are the product of revision of the initially proposed RECIST in 2000, 9 use unidimensional measurements of the longest diameter of tumor target lesions. In RECIST 1.1, a greater than 20% increase in the sum of the target lesions is considered progression and a greater than 30% decrease is considered a partial response (PR), with the presence of new lesions automatically classified as progressive disease (PD). In response to the recognition of unconventional patterns of response observed in clinical trials of immune checkpoint inhibitors, several new immune therapyrelated criteria have been proposed for following tumor response to immune checkpoint inhibitor therapy.
The unidimensional iRRC 7 are a simplified version of the initially proposed immune-related response criteria 1 and are similar to RECIST 1.1 in that unidimensional measurements of target lesions are summed between time points and the same thresholds are utilized to call PD and PR. However, unlike RECIST 1.1, both the initially proposed bidimensional iRRC and the subsequent unidimensional iRRC use a metric of tumor burden to follow response, allowing for inclusion of new lesions in the measured tumor lesion sums used to calculate response, and they require serial imaging to confirm PD. This is in contrast to RECIST 1.1, according to which new lesions are automatically considered progression and no confirmatory computed tomography (CT) image is required to classify a response as PD. It is unclear whether the use of this metric of tumor burden has an advantage in more accurately classifying tumor response in the setting of immune checkpoint inhibitor therapy. Interestingly, in a recently published study by Nishino et al. 10 of 56 patients with NSCLC who were receiving anti-PD-1 therapy, the unidimensional iRRC resulted in identical response rates, albeit a longer time to progression, than with use of RECIST 1.1; the authors noted that there were no cases of radiologic pseudoprogression in their study. This longer time to progression was attributed to the requirement of a confirmatory CT scan for cases of suspected PD according to these iRRC criteria. More recent modifications of the unidimensional iRRC include the immune-related RECIST (irRECIST) [10] [11] [12] and the immune-modified RECIST (imRECIST), 13 both of which seek to limit number of target lesions and new lesions included in the metric of tumor burden.
In 2017, immune criteria were proposed in a published consensus statement by the RECIST working group, 8 which established new guidelines for clinical trial measurement of tumor in patients with cancer who 4 This is partly due to the fact that data are still lacking in determining the superiority of any one set of immune criteria for the characterization of response to therapy in the setting of immune checkpoint inhibitor therapy. Here, we have compared tumor response to immune checkpoint inhibition in NSCLC in a real-world clinical practice and examined the utility of RECIST 1.1, the unidimensional iRRC, and the iRECIST in classifying therapy response, including radiologic pseudoprogression.
Materials and Methods

Collection of Clinical Data
Approval for this study was obtained from the institutional review board at our institution. All adult patients with NSCLC treated with anti-PD-1 agents at our institution between June 2013 to February 2016 were retrospectively identified. Electronic medical records were reviewed to determine clinical assessment of response to anti-PD-1 therapy (tumor response, stable disease, or progression). Patients who did not have a baseline CT scan within 60 days of starting therapy and at least one follow-up imaging examination while receiving anti-PD-1 therapy were excluded from the study. Patients without accessible clinical oncology progress notes while receiving anti-PD-1-therapy were also excluded from the study. All patients with clinically suspected radiologic pseudoprogression, as evidenced by continuation of anti-PD-1 therapy despite increased tumor size or the presence of new lesions on reimaging, were identified.
Radiologic Analysis
Cross-sectional imaging of all patients included in the study was analyzed for radiologic response for at least one imaging time point after the start of anti-PD-1 therapy. Radiologic tumor responses during anti-PD-1 therapy were compared by using RECIST 1.1, 6 the unidimensional iRRC, 7 and iRECIST 8 (see Table 1 ) criteria. Although the publication describing the unidimensional iRRC does not detail the number of target lesions and thresholds for target nodal disease, the authors state that they used the criteria of the original bidimensional iRRC with the exception of the adoption of RECIST 1.1 short axis nodal measurements, unidimensional measurements of target lesion long axis, and RECIST 1.1 thresholds for PD and PR. 7 As such, we adopted a nodal threshold of 15 mm in the short axis and a limit of five lesions per organ and 10 new visceral lesions to calculate target lesion sums. 1 The cases of patients identified by their oncologists as having clinically suspected radiologic pseudoprogression were analyzed to determine whether subsequent reimaging demonstrated confirmed progression.
Statistical Analysis
Excel Toolpak (version14.6.7. Microsoft, Redmond, WA) was used for statistical analysis of data, including calculation of means and Student's t tests.
Results
Patient Population
A total of 228 consecutive adult patients began receiving anti-PD-1 therapy at our institution, of whom 166 met the study inclusion criteria and were evaluable. These patients ranged in age from 34 to 88 years (mean age 73 years), and NSCLC, including adenocarcinoma (73%), squamous cell carcinoma (22%), adenosquamous (1%), or other NSCLC (4%), had been diagnosed in all of them. Of the evaluable patients, 80% received nivolumab and the remaining 20% received pembrolizumab as non-first-line therapy. A total of 62 patients were excluded from the study because they did not have available clinical data (patients who transferred care to another institution or for whom notes were not accessible because their treatment was performed at satellite offices) or on account of a lack of radiologic data at baseline or during the period in which they received anti-PD-1 therapy at our institution.
Most Clinically Suspected Cases of Radiologic Pseudoprogression in NSCLC Being Treated with Anti-PD-1 Agents Were True Cancer Progression
In our patient population, the overall radiologic response rate (complete response [n ¼ 4] þ PR [n ¼ 32]) was 22% during the study period, as determined by RECIST 1.1, which is the current criterion standard for assessment of response to therapy in lung cancer. In all, 53% of patients (n ¼ 88) exhibited progression according to RECIST 1.1 at first reimaging, with three of these patients (2% of the overall population) demonstrating evidence of radiologic pseudoprogression.
Two of the three cases of radiologic pseudoprogression demonstrated a pattern of enlargement of the primary tumor within the first 3 months of therapy with subsequent tumor regression (Fig. 1) . One of the three patients with pseudoprogression exhibited an initial decrease in size of the primary tumor with the development of new pulmonary lesions (Fig. 2) . At 4 to 6 months of therapy, all cases of radiologic pseudoprogression had begun to reveal evidence of treatment response. Patients 1 and 3, both of whom received nivolumab as third-line therapy, were alive at the time of writing of this article, which was nearly 3 years from the start of anti-PD-1 therapy. Patient 2 stopped receiving anti-PD-1 therapy because of drug toxicity and died 20 months from the start of nivolumab as third-line therapy.
A review of the electronic medical records revealed that of those patients with radiologic evidence of tumor enlargement or new lesions at first reimaging, 15 (9% of the cohort) were clinically suspected of radiologic pseudoprogression owing to clinical improvement despite imaging evidence of an increase in tumor burden, and they continued receiving anti-PD-1 therapy. In addition to the three cases of radiologic pseudoprogression with progression at the first reimaging according to RECIST 1.1, one patient with stable disease at the first reimaging according to RECIST 1.1, one additional patient with RECIST1.1 stable disease at the first reimaging (Supplementary Table 1 , patient 4) did not meet the measurement criteria for progression by any of the criteria but manifested a pattern of enlargement at the first reimaging and a subsequent 18% decrease in target lesion sums at second reimaging, which was suggestive of a pattern of radiologic pseudoprogression. This patient remained stable during anti-PD-1 therapy for 18 months before progressing while still receiving therapy.
The Unidimensional iRRC and iRECIST
As detailed earlier in this article, retrospective measurement of serial imaging of patients with PD according to RECIST 1.1 revealed three patients with radiologic pseudoprogression, all of whom were identified by their oncologist during routine clinical management as having clinically suspected radiologic pseudoprogression. Analysis of the imaging of these three patients with the response criteria revealed that the unidimensional iRRC and iRECIST more accurately identified potential pseudoprogression when compared with RECIST 1.1. When analyzed by RECIST 1.1, all three of the patients exhibiting pseudoprogression were considered to have progression at first reimaging ( Table 2 , patients 1-3). By comparison, when the imaging for these patients was analyzed by using the unidimensional iRRC or iRECIST, no patients were confirmed as having PD at first reimaging because both methods require suspected PD to be confirmed with subsequent reimaging at least 1 month later. It should be noted that despite resulting in initial classification of these patients as having PD, RECIST 1.1 also correctly identified their cases as nonprogression at second reimaging.
For example, the unidimensional iRRC correctly identified one of the patients with radiologic pseudoprogression (i.e., a patient who had an initial decrease in tumor size but development of new lesions at first reimaging), as a case of nonprogression (see Table 2 , patient 1) because the overall tumor burden did not meet the criteria for PD. According to iRECIST, this patient (patient 1) was initially considered to have unconfirmed PD (iUPD), that is, disease that meets criteria for progression but has not be confirmed as progression disease by subsequent reimaging as required by iRECIST. In this patient, tumor remained iUPD at reimaging. In contrast, this patient was automatically considered to have PD according to RECIST 1.1 because of the presence of new lesions.
Of the remainder of the patients with initially clinically suspected radiologic pseudoprogression (n ¼ 12), 50% (n ¼ 6) were classified as having stable disease and 50% (n ¼ 6) were classified as having PD according to Figure 2 . Radiologic pseudoprogression in a patient with NSCLC who was receiving nivolumab therapy. (A) Axial computed tomography images from a 68-year-old patient with adenocarcinoma of the lung after a lobectomy with known pulmonary metastasis (arrows) at baseline. (B) At 2 months of therapy there were new and enlarged pulmonary nodules. By 3 months of therapy, the pulmonary nodules had decreased in size and number (C) and at 6 months of therapy they had nearly resolved (D). Table 3 , patients 4-15) criteria performed similarly in terms of generated target lesion sums but with several notable differences. A major difference was that patients initially classified as having PD according to RECIST 1.1 at first reimaging were deferred for second reimaging assessment according to the iRRC and iRECIST. Although the actual calculated percent change in measured tumor differed among the tested methods, the assessment of suspected PD and stable disease for each patient at second reimaging was identical for all but one of the patients (patient 15). The calculated percent change in tumor sums for two patients (patients 11 and 15) highlighted the differences among the tested criteria.
Use of the Unidimensional iRRC Can Result in Greater Calculated Changes in Tumor Increases in the Setting of New Lesions Than with Use of RECIST 1.1 and iRECIST
The unidimensional iRRC allows for the inclusion of new lesions in the metric of tumor burden, which the RECIST 1.1 and iRECIST do not, as well as the inclusion of a greater number of total target lesions than either of the two other criteria. An example of this is demonstrated in the assessment of calculated percent change between the two evaluated time points for patient 11, with a significantly greater sum calculated on the basis of the unidimensional iRRC method (a 97% increase [see Supplementary Table 2 ]) compared with the sums calculated on the basis of RECIST 1.1 and iRECIST (14% [see Supplementary Tables 1 and 3 , respectively]), which do not allow for inclusion of new lesions in the calculated percent change. However, in this example, the calculated tumor change did not result in significant differences in initial assessment of tumor response because this patient was considered to have PD according to RECIST 1.1 and iUPD according to iRECIST on account of the presence of new lesions and to have met the criteria for suspected PD according to the unidimensional iRRC, though no confirmatory scan was available for the immune criteria assessments because this patient's anti-PD-1 therapy was subsequently discontinued.
In the comparative analysis of the entire cohort of 166 patients according to the RECIST 1.1, unidimensional iRRC, and iRECIST criteria, we found that for those patients with a PR (n ¼ 32) and those with a complete response (n ¼ 4), although the percent change in the sum of target lesions with use of the iRRC may have differed from the percent change with use of the RECIST1.1 and the iRECIST criteria, the assessments of response to therapy at first reimaging were identical across all three criteria for patients in these response groups. For patients with stable disease (n ¼ 42), the assessment of response was identical among the three sets of criteria except in the case of one patient. For this patient, who had stable disease according to RECIST 1.1, the ability to include more lesions with the unidimensional iRRC resulted in suspected PD at first reimaging, whereas the change in target sum yielded an assessment of stable disease according to RECIST 1.1 and iRECIST.
Disparity was also observed in the category PD. Here we observed that a total of three of the 88 patients (3%) with PD according to RECIST 1.1 had disparate immune criteria assessment results regarding meeting the threshold for suspected progression. In all three patients (including patient 1, who was discussed earlier in this article), significant tumor enlargement or the presence of new lesions at first follow-up mandated an assessment of PD by RECIST1.1 and iUPD by iRECIST. In contrast, when these patients were analyzed by the unidimensional iRRC criteria, the change in target lesion sums did not meet the criteria for suspected PD.
However, with use of the unidimensional iRRC and iRECIST, the requirement for a confirmatory CT scan for suspected PD (>20% change in target lesion sums) mandates a confirmatory CT scan at least 1 month later. With the exception of the patients with clinically suspected radiologic pseudoprogression, those patients with PD according to RECIST 1.1 did not have subsequent reimaging because they were switched to a new line of therapy or died. All five patients in whom PD was suspected according to the unidimensional iRRC and who continued to receive therapy for reimaging (see Supplementary Table 2) were assessed as having stable disease at second reimaging. Similarly, of the six patients with suspected iRECIST iUPD at first reimaging who continued on therapy (Supplementary Table 3) , five were assessed to have stable disease and one confirmed to have PD at second reimaging.
Mixed Tumor Response Can Be Mistaken for Nonprogression When the Unidimensional iRRC Are Used
One of the 15 patients initially clinically suspected of radiologic pseudoprogression (patient 15) exhibited a mixed tumor response that was correctly identified as progression according to RECIST 1.1 and iRECIST but was classified as stable disease according to the iRRC. At first reimaging, this patient demonstrated mild enlargement of the primary tumor (a 13% increase in size) along with a newly enlarged right supraclavicular lymph node (a 15-mm short axis), which was considered progression according to RECIST 1.1 and according to iRECIST (iUPD). At the subsequent reimaging, the size of primary tumor had significantly decreased in caliber (a 21% interval decrease in size); however, this decrease was accompanied by substantial enlargement of the noted right supraclavicular lymph node (now 21 mm in the short axis) and subsequently proved to be metastatic. According to the unidimensional iRRC, the tumor response at second reimaging was classified as stable disease because the overall tumor burden had significantly decreased despite the presence of new and enlarged lesions. According to RECIST 1.1, this response at second reimaging was again considered PD. According to iRECIST, this further increase in the size of the supraclavicular lymph node by more than 5 mm confirmed progression for the first reimaging and was considered unconfirmed PD (iUPD) for the second reimaging time point. Therefore, this patient was correctly identified as having PD according to RECIST 1.1 and iRECIST at first and second reimaging because of the fact that both these sets of criteria consider new lesions to be progression. In contrast, according to iRRC, assessment of this patient was deferred to second reimaging, at which time the overall burden of disease significantly decreased and was classified as stable disease (a 19% decrease in tumor burden).
Discussion
Radiologic pseudoprogression is an important but uncommon occurrence in the setting of anti-PD-1 therapy for advanced NSCLC. Pseudoprogression of the tumor on imaging is thought to be a manifestation of tumor infiltration by an activated immune response as a result of successful anti-PD-1 therapy. It is clinically suspected when imaging shows evidence of progression, such as tumor enlargement or the presence of new lesions but the patient appears clinically stable or improved. In this study, most (80%) of the patients with NSCLC who were receiving anti-PD-1 therapy agents and were suspected of having radiologic pseudoprogression were ultimately proved to have true progression. The small number of cases of radiologic pseudoprogression observed in this study (2%) is in keeping with the low rate of occurrence of this phenomenon observed in the anti-PD-1 treatment of NSCLC, which as been reported in the literature as ranging from 0% to 5%. 4, 5, 10 The unidimensional iRRC and iRECIST have recently been proposed as improvements over RECIST 1.1 in the setting of immunotherapy. The unidimensional iRRC use a metric of tumor burden to assess changes between imaging rather than only following changes in individual lesions identified on baseline imaging. This allows for the assessment of stable disease or PR if the overall tumor burden is decreased despite the development of new lesions. In addition, the iRRC require validation of PD with an additional CT scan at least 1 month later. The iRECIST is similar to RECIST 1.1 in that only baseline target lesions are used to calculate percent change in tumor sums and new lesions are considered to indicate PD; however, it differs from RECIST 1.1 in that all patients with tumor suspected of PD is considered unconfirmed until demonstration of further progression at subsequent reimaging.
In this study, neither RECIST 1.1 nor the newer unidimensional iRRC or iRECIST were completely accurate in differentiating radiologic pseudoprogression from true PD. At the first reimaging, the unidimensional iRRC were superior in that they more clearly characterized as nonprogression one case of radiologic pseudoprogression with new lesions (patient 1). The remaining cases were deferred for complete assessment until the second reimaging, at which time the unidimensional iRRC and iRECIST classified cases of radiologic nonprogression or unconfirmed progression (iUPD), respectively. Finally, one case of confirmed progression that was initially thought to represent radiologic pseudoprogression was classified as stable disease at second reimaging (patient 15) with use of the unidimensional iRRC, whereas it was correctly classified as progression by RECIST 1.1 and confirmed PD (iCPD) by iRECIST.
These findings are supported by a study by Tazdait et al. 20 (also a retrospective study of immune response criteria in patients with NSCLC who are receiving anti-PD-1 therapy), which found that the RECIST 1.1 criteria underestimated tumor response relative to immune criteria. It should be noted that Tazdait et al. 20 cited a rate of pseudoprogression (8%) that was higher than the rate observed in our study (2%) or the rate typically reported for patients with NSCLC who are receiving anti-PD-1 agents (0%-5%). Our study also differs from the publication by Tazdait et al. 20 in that it represents a real-world clinical experience of anti-PD-1 therapy in the management of NSCLC and examines the unidimensional iRRC rather than the irRECIST, which are another iteration of immune criteria based on tumor burden. The irRECIST criteria have been used in several studies by Nishino et al. [10] [11] [12] and appear similar to the newly reported imRECIST described by Hodi et al. 13 in that both of these criteria seek to limit the target lesions and new lesions included in the measurement of tumor burden using RECIST 1.1 methods. We chose the unidimensional iRRC because they allow for a robust measure of tumor burden while preserving the RECIST 1.1 methods for tumor measurement, thus permitting comparison between a metric of tumor burden (the unidimensional iRRC), iRECIST (which considers new lesions separately and more closely restricts the number of target lesions considered per organ), and the conventional RECIST 1.1 criteria. However, it is noted that there is some evidence to suggest that reducing the number of lesions from five target lesions per organ (10 target lesions in total) to two target lesions per organ (five target lesions in total) may not significantly affect the utility of the immune criteria. 21 Potential limitations to the interpretation of the results from this study include its retrospective nature, its modest cohort size, the predominance of nivolumab as a therapeutic agent (80%), and the fact that the patient cohort studied underwent therapy with an anti-PD-1 agent as non-first-line therapy. It is unclear whether the estimated rate of radiologic pseudoprogression of 2% identified in this study of NSCLC patients receiving anti-PD-1 therapy as second line agents, will reflect the rate of radiologic pseudoprogression in NSCLC patients receiving anti-PD-1 agents as 1st line therapy, as commonly practiced currently. Since NSCLC patients receiving anti-PD-1 therapy as first-line agents now typically are enriched for those with higher tumor expression of PD-1, sometimes in combination with other therapeutics that may enhance response rates, it is possible that the rate of radiologic pseudoprogression will differ from our studied NSCLC patient population. Future prospective studies will be needed to further examine the rates of radiologic pseudoprogression and performance of the various available imaging criteria in this evolving therapeutic landscape.
In summary, although radiologic pseudoprogression is often clinically suspected in patients with NSCLC who are receiving anti-PD-1 therapy, most such patients actually exhibit true progression. The currently available radiologic response criteria do not adequately differentiate between radiologic pseudoprogression and true progression in a timely manner, although the unidimensional iRRC and iRECIST may provide an advantage in more accurate classification of disease response. The newly described imRECIST remain untested and will be examined in our future studies. In considering use of the unidimensional iRRC and iRECIST, the requirement of additional imaging in cases of suspected progression does incur an additional cost in terms of expenditure of extra time on a potentially ineffective therapy and financial cost of additional imaging. This additional cost must be weighed against the estimated frequency of pseudoprogression in a given patient population, which in the case of a patient with NSCLC receiving single-agent anti-PD-1 therapy is very low. An understanding of the relative biases of these criteria for application in the setting of immune checkpoint inhibitor therapy is important when choosing among these response criteria to interpret disease response.
